White blood cell B lymphocyte plasma cell producing antibodies isolated on white background

BioFactura is committed to identifying and fulfilling unmet global biomedical and national biodefense needs. BioFactura is applying its StableFastTM Biomanufacturing Platform to develop a portfolio of high-value biosimilars (generic biological drugs). The Company is also focused on bringing to market a drug for the treatment of smallpox and is conducting research and development of an Ebola therapeutic. BioFactura is evaluating other opportunities in both commercial and biodefense markets.